Comparative study of β‐catenin and <scp>CD</scp>44 immunoexpression in oral lichen planus and squamous cell carcinoma

Zargaran, Massoumeh; Baghaei, Fariba; Moghimbeigi, Abbas

doi:10.1111/ijd.14007

Cited by 12 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In addition, the results of Zargaran et al's research were acceptable regarding the expression of CD44 marker in lichen planus that are consistent with the results of present research. 17 The results of Neppelberg et al's research showed that CD44 marker expression was acceptable in areas with oral lichen planus in epithelial tissues as well as areas with compact tissue, which is consistent with the results of our research. 18 The findings of Chaiyarit et al's research showed that CD44 is a desirable indicator for the diagnosis of oral lichen planus from other epithelial dysplastic lesions that is consistent with the results of our research.…”

Section: Discussionsupporting

confidence: 92%

“…E-cadherins make connections in epithelial tissues thus keeping the epithelial cells together. 17 Many epithelial neoplasms, including oral squamous cell carcinoma (OSCC), show the changes in the expression of E-cadherin protein. The possibility of this change in extent causes a defect in the ability of the cells to attach to each other and facilitates separation from the primary tumor and attachment to the substrate components and progression to the surrounding tissues.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma

Abdal¹,

Mostafazadeh²,

Ghorbani³

2021

CODS - Journal of Dentistry

View full text Add to dashboard Cite

a premalignant condition. 12 Oral leukoplakia, OLP, and OSCC are the most common oral diseases with specific clinical and histological features and in most cases are associated with chronic inflammation in adjacent connective tissue. 13 Decreased or increased expression of some molecular-protein markers in suspected malignant lesions has been somewhat effective in the early detection of oral cancer. Among many protein factors, two are clinically important including CD44 and E-cadherin. 14 CD44 is a membrane glycoprotein with various isoforms of V10 to V10 that results from different mRNA expression.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma

Abdal¹,

Mostafazadeh²,

Ghorbani³

2021

CODS - Journal of Dentistry

View full text Add to dashboard Cite

show abstract

“…As has been observed, the expression of CD44 was significantly lower in OSCC in comparison with oral lichen planus which is a precancerous state of OSCC, indicating that CD44 might trigger the malignant conversion from precancerous state to cancer [105]. In pleomorphic adenoma, knockdown of CD44 not only impaired the malignant behaviors of tumor-initiating cells in vitro, but also suppressed tumorigenesis in xenograft mice [106].…”

Section: Cd44 and Tumor Initiationmentioning

confidence: 51%

CD44 as a tumor biomarker and therapeutic target

et al. 2020

View full text Add to dashboard Cite

CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem cells, and promotes epithelial-mesenchymal transition. CD44 is involved in the regulation of diverse vital signaling pathways that modulate cancer proliferation, invasion, metastasis and therapy-resistance, and it is also modulated by a variety of molecules in cancer cells. In addition, CD44 can serve as an adverse prognostic marker among cancer population. The pleiotropic roles of CD44 in carcinoma potentially offering new molecular target for therapeutic intervention. Preclinical and clinical trials for evaluating the pharmacokinetics, efficacy and drug-related toxicity of CD44 monoclonal antibody have been carried out among tumors with CD44 expression. In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in carcinogenesis and cancer progression as well as the potential CD44-targeting therapy for cancer management.

show abstract

“…Oral squamous cell carcinoma is, therefore, an important health problem in the global community (2). Oral squamous cell carcinoma occurs in a multi-step process, from the step-by-step accumulation of genetic mutations, which is morphologically known as a precancerous lesion (3). But, mere microscope-based clini-cal signs cannot determine the progression of a precancerous lesion to malignancy.…”

Section: Introductionmentioning

confidence: 99%

LncRNA GHET1 and LncRNA ZXF2 as New Biomarkers in Oral Squamous Cell Carcinoma in Relation to Clinicopathological Variables

et al. 2023

View full text Add to dashboard Cite

Background: The utilization of molecular techniques in detecting cancer has resulted in an improved prediction of outcomes. Oral squamous cell carcinoma (OSCC) is a prevalent illness that is frequently detected in its late stages. Therefore, finding molecular biomarkers that lead to the early detection of OSCC is of great importance. Objectives: This study aimed at evaluating the expression levels of long non-coding RNA (LncRNA) gastric carcinoma highly expressed transcript 1 (GHET1) and lncRNA ZXF2 in OSCC patients and their relationship with clinical pathology variables due to biomarker discovery and early diagnosis of OSCC. Methods: Tissue sampling was performed after selecting 30 OSCC patients and 30 healthy individuals from Emam-Khomeini Hospital, Tehran, Iran. Then, RNA extraction and cDNA synthesis were performed from these samples, using the relevant kits and their quantity and quality were measured, using nanodrop and agarose gel electrophoresis, respectively. For molecular biomarker identification and validation, real-time PCR (RT-PCR) was utilized to assess the expression of lncRNA GHET1 and lncRNA ZXF2. Data analysis was done, using GraphPad prism V.8 software. Results: The results showed that the expressions of both lncRNA GHET1 and lncRNA ZXF2 in OSCC tumor tissue increased compared to normal tissue (P < 0.0001). Receiver operating characteristic (ROC) analysis indicated that lncRNA GHET1 and lncRNA ZXF2 have the capability to be employed as biomarkers for OSCC detection. However, no significant relationship was observed between lncRNA GHET1 and lncRNA ZXF2 expressions with clinicopathological variables such as tumor stage and grade as well as patients' age. Conclusions: LncRNA GHET1 and lncRNA ZXF2 have the potential to be used as biomarkers in the early detection of OSCC and evaluating their expression in clinical settings are recommended. The use of these biomarkers in the early detection of OSCC can prevent the high mortality rate of OSCC patients. In the current study, the important role of the studied lncRNAs in OSCC diagnosis was shown. However, further studies are needed to confirm this.

show abstract

Comparative study of β‐catenin and CD44 immunoexpression in oral lichen planus and squamous cell carcinoma

Abstract: According to the findings of this study, β-catenin and CD44 can differentiate between behavior of OLP and OSCC, while the precancerous nature of OLP and malignant transformation potential of it are not suggested.

Cited by 12 publications

References 24 publications

Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma

Comparison of E-cadherin and CD44 Markers Expression in Oral Lichen Planus, Oral Leukoplakia and Oral Squamous Cell Carcinoma

CD44 as a tumor biomarker and therapeutic target

LncRNA GHET1 and LncRNA ZXF2 as New Biomarkers in Oral Squamous Cell Carcinoma in Relation to Clinicopathological Variables

Contact Info

Product

Resources

About